Halozyme Therapeutics, Inc.

HALO Healthcare Biotechnology

Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024.

Revenue
+39.2%
EPS
+45.6%
Free cash flow
−58.6%
Total debt
+115.1%

Quarter to September 2026, against a year earlier

103.93 19.03 −15.48%
Market cap
$14.0B
P/E
29.5×
Fwd P/E
17.9×
Dividend yield
—
F-score
5/9
Altman Z
3.46
Beneish M
−2.59
Dividend safety
n/a
Sep '26 From the 10-Q filed 5 Nov Jun '26 Mar '26 Dec '25 Older periods
Piotroski F-Score
6 5 5 5

+8 more TTM periods

ROE
216.38% 173.67% 99.40% 153.59%
ROA
17.05% 17.86% 14.33% 13.81%
ROIC
19.87% 18.13% 15.64% 14.31%
Return on Tangible Assets
33.41% 61.47% 48.31% 43.39%
Average Days of Receivables
106.43 100.00 110.82 115.33
Free Cash Flow per Share
7.89 6.87 5.65 5.38
Free Cash Flow
898.27 806.22 667.65 644.59
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026